PURPOSE: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.
METHOD: Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.
RESULTS: There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.
CONCLUSION: We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.
TRIAL REGISTRATION: ANZCTR 26180001220257, registered 20/07/2018.
Neurogastroenterology and motility · 2026
Lung cancer (Amsterdam, Netherlands) · 2026
Addiction (Abingdon, England) · 2019
Journal of adolescent and young adult oncology · 2019
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2019
Journal of the National Comprehensive Cancer Network : JNCCN · 2019
